Lilly To Start Phase III Trials in Diabetic Peripheral Neuropathy For LY-333531
Lilly is expanding its Phase III program for the protein kinase C-beta inhibitor LY-333531 to include diabetic peripheral neuropathy
More from Archive
More from Pink Sheet
• By
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
• By
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
• By
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.